Nabi Biopharmaceuticals Announces Second Quarter 2007 Financi...( Revenues $ 20873 ...),Health

Revenues $ 20,873 $ 20,374 $ 44,621 $ 39,891

Cost of products sold 11,680 14,366 26,487 28,882

Gross margin 9,193 6,008 18,134 11,009

Selling, general and

administrative expense 8,574 11,143 18,587 22,999

Research and development

expense 9,048 8,883 19,104 17,661

Operating loss (8,429) (14,018) (19,557) (29,651)

Interest income 1,419 945 2,999 2,008

Interest expense (886) (905) (1,803) (1,858)

Other income, net 2,561 317 2,559 382

Loss from continuing

operations before

income taxes (5,335) (13,661) (15,802) (29,119)

Income taxes - - (190) -

Loss from continuing

operations (5,335) (13,661) (15,992) (29,119)

Net income (loss) from

discontinued operations 557 (1,163) 185 (3,782)

Net loss $ (4,778) $ (14,824) $ (15,807) $ (32,901)

Basic and diluted (loss)

income per share:

Continuing operations $ (0.09) $ (0.22) $ (0.26) $ (0.48)

Discontinued operations 0.01 (0.02) 0.00 (0.06)

Basic and diluted loss

per share (0.08) (0.24) (0.26) (0.54)

Basic and diluted

weighted average shares

outstanding 61,280 60,977 61,192 60,653

Nabi Biopharmaceuticals

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

'/>"/>

SOURCE Nabi Biopharmaceuticals Copyright©2007 PR Newswire.

0 GOOD